These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 16834832

  • 21. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
    Lee P, Shu L, Xu X, Wang CY, Lee MS, Liu CY, Hong JP, Ruschel S, Raskin J, Colman SA, Harrison GA.
    Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
    [Abstract] [Full Text] [Related]

  • 22. The influence of educational information on depressed outpatients treated with escitalopram: a semi-naturalistic study.
    Leinonen E, Niemi H.
    Nord J Psychiatry; 2007 Jun; 61(2):109-14. PubMed ID: 17454725
    [Abstract] [Full Text] [Related]

  • 23. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Jun; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 24. Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
    Bech P, Lönn SL, Overø KF.
    J Clin Psychiatry; 2010 Feb; 71(2):121-9. PubMed ID: 19961809
    [Abstract] [Full Text] [Related]

  • 25. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
    Demyttenaere K, Andersen HF, Reines EH.
    Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
    [Abstract] [Full Text] [Related]

  • 26. Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine.
    Baldwin D, Bridgman K, Buis C.
    J Psychopharmacol; 2006 Jan; 20(1):91-6. PubMed ID: 16204325
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 28. Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study.
    Anghelescu IG, Kohnen R, Szegedi A, Klement S, Kieser M.
    Pharmacopsychiatry; 2006 Nov; 39(6):213-9. PubMed ID: 17124643
    [Abstract] [Full Text] [Related]

  • 29. Escitalopram therapy for major depression and anxiety disorders.
    Baldwin DS, Reines EH, Guiton C, Weiller E.
    Ann Pharmacother; 2007 Oct; 41(10):1583-92. PubMed ID: 17848424
    [Abstract] [Full Text] [Related]

  • 30. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression.
    Baldwin DS, Hawley CJ, Abed RT, Maragakis BP, Cox J, Buckingham SA, Pover GH, Ascher A.
    J Clin Psychiatry; 1996 Oct; 57 Suppl 2():46-52. PubMed ID: 8626363
    [Abstract] [Full Text] [Related]

  • 31. The onset of effect for escitalopram and its relevance for the clinical management of depression.
    Wade A, Friis Andersen H.
    Curr Med Res Opin; 2006 Nov; 22(11):2101-10. PubMed ID: 17076970
    [Abstract] [Full Text] [Related]

  • 32. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.
    Hewett K, Chrzanowski W, Schmitz M, Savela A, Milanova V, Gee M, Krishen A, Millen L, Leary MO, Modell J.
    J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695
    [Abstract] [Full Text] [Related]

  • 33. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A, Bose A, Alexopoulos GS, Gommoll C, Li D, Gandhi C.
    Clin Drug Investig; 2007 Jul; 27(7):481-92. PubMed ID: 17563128
    [Abstract] [Full Text] [Related]

  • 34. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G, Beeské S, Stahl SM.
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [Abstract] [Full Text] [Related]

  • 35. Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder.
    Kasper S, Ebert B, Larsen K, Tonnoir B.
    Int J Neuropsychopharmacol; 2012 Jul; 15(6):715-25. PubMed ID: 22008735
    [Abstract] [Full Text] [Related]

  • 36. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    Montgomery SA, Möller HJ.
    Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
    [Abstract] [Full Text] [Related]

  • 37. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P.
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [Abstract] [Full Text] [Related]

  • 38. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 Feb; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

  • 39. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
    Schöne W, Ludwig M.
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():16-8. PubMed ID: 7959520
    [Abstract] [Full Text] [Related]

  • 40. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram.
    Trivedi MH, Cutler AJ, Richards C, Lasser R, Geibel BB, Gao J, Sambunaris A, Patkar AA.
    J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.